Paul A. Ragusa

Verax Biomedical, Inc. develops rapid tests for detecting bacterial contaminants in blood cells and tissues. The firm's first target application for its technology is to test for the presence of bacterial contaminants in platelets and bacterial contaminants in platelets and red blood cells represent the greatest lethal infectious risks in transfusion medicine today and no rapid, simple methods are presently available to effectively address this threat. Verax Biomedical was founded by Joe R. Sanders and Joe L. Straight in 1999 and is headquartered in Marlborough, MA.

Verax Biomedical, Inc. develops rapid tests for detecting bacterial contaminants in blood cells and tissues. The firm's first target application for its technology is to test for the presence of bacterial contaminants in platelets and bacterial contaminants in platelets and red blood cells represent the greatest lethal infectious risks in transfusion medicine today and no rapid, simple methods are presently available to effectively address this threat. Verax Biomedical was founded by Joe R. Sanders and Joe L. Straight in 1999 and is headquartered in Marlborough, MA.

Verax Biomedical, Inc. develops rapid tests for detecting bacterial contaminants in blood cells and tissues. The firm's first target application for its technology is to test for the presence of bacterial contaminants in platelets and bacterial contaminants in platelets and red blood cells represent the greatest lethal infectious risks in transfusion medicine today and no rapid, simple methods are presently available to effectively address this threat. Verax Biomedical was founded by Joe R. Sanders and Joe L. Straight in 1999 and is headquartered in Marlborough, MA.

Verax Biomedical, Inc. develops rapid tests for detecting bacterial contaminants in blood cells and tissues. The firm's first target application for its technology is to test for the presence of bacterial contaminants in platelets and bacterial contaminants in platelets and red blood cells represent the greatest lethal infectious risks in transfusion medicine today and no rapid, simple methods are presently available to effectively address this threat. Verax Biomedical was founded by Joe R. Sanders and Joe L. Straight in 1999 and is headquartered in Marlborough, MA.

Verax Biomedical, Inc. develops rapid tests for detecting bacterial contaminants in blood cells and tissues. The firm's first target application for its technology is to test for the presence of bacterial contaminants in platelets and bacterial contaminants in platelets and red blood cells represent the greatest lethal infectious risks in transfusion medicine today and no rapid, simple methods are presently available to effectively address this threat. Verax Biomedical was founded by Joe R. Sanders and Joe L. Straight in 1999 and is headquartered in Marlborough, MA.